Genus Claims Require Disclosure of “Representative Species Encompassing the Breadth of the Genus”

by McDermott Will & Emery

AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc.

Finding that a patent specification did not disclose a representative number of antibody species within the claimed genus, the U.S. Court of Appeals for the Federal Circuit upheld a jury verdict finding claims were invalid for lack of written description.  AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., Case Nos. 13-1338; -1346 (Fed. Cir., July 1, 2014) (Lourie, J.) (O’Malley, J. concurring).

AbbVie’s patent claims were drawn to human antibodies that are useful for treatment of psoriasis and rheumatoid arthritis.  The claims require that antibodies bind to a protein called IL-12 at a certain measurable binding strength (koff).  The specification disclosed about 300 different antibodies with these characteristics, all of which were derived from a single “parent” antibody.  As such, these 300 antibodies are more than 90 percent identical to one another within the region that binds to the IL-12, and over 200 of these share a 99.5 percent amino acid sequence similarity in that region.  At trial, Janssen established that its allegedly infringing IL-12 antibody was structurally different from AbbVie’s disclosed antibodies and, further, that antibodies with 80 percent sequence identity to AbbVie’s disclosed antibodies could bind to totally different targets than IL-12.  The jury found that the claims invalid as lacking a sufficient written description, enablement and for obviousness.  AbbVie appealed.

On appeal the Federal Circuit agreed that the written description did not provide a representative number of species evincing that the inventors truly invented the full scope of the genus.  The Court concluded that the claims recited antibodies based on functional characteristics and that this functional genus would encompass antibodies with a wide variety of structural characteristics.  The Court noted that, “[a]lthough the number of the described species appears high quantitatively, the described species are all of the similar type and do not qualitatively represent other types of antibodies encompassed by the genus.”  Analogizing the scope of a genus to a plot of land, the Court found that AbbVie’s disclosed antibodies were concentrated within one “corner of the genus” and that AbbVie did not describe “sufficient representative species encompassing the breadth of the genus,” but only “a research plan, leaving it to others to explore the unknown contours of the claimed genus.”

In response to AbbVie’s argument that the koff limitation provided the requisite representativeness across the genus, the Court found that “[t]he koff rate is merely a desired result, rather than the actual means for achieving that result.”  The Court reiterated the importance of providing “a reasonable structure-function correlation” when pursuing functional claims:

Functionally defined genus claims can be inherently vulnerable to invalidity challenge for lack of written description support, especially in technology fields that are highly unpredictable, where it is difficult to establish a correlation between structure and function for the whole genus or to predict what would be covered by the functionally claimed genus.

Practice Note:  Although not explicit, the Court’s warning seems to be directed to patent holders in the “highly unpredictable” life sciences space.  Sufficient written description support for functional genus claims in the life sciences space seems to require either an explicit disclosure of a structure-function correlation, or else a disclosure of multiple species sharing the claimed function, but having a wide variety of different structures.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDermott Will & Emery | Attorney Advertising

Written by:

McDermott Will & Emery

McDermott Will & Emery on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.